Nov 08, 2021 / 06:50PM GMT
Judah C. Frommer - Crédit Suisse AG - Research Division - Senior Analyst
Hello, and welcome to the 2021 Credit Suisse Healthcare Conference. I'm Judah Frommer, Senior Biotech Analyst here at Credit Suisse, and we're thrilled to have David Meline, CFO; and Lavina Talukdar, Head of IR, from Moderna with us.
With that, I think we can jump right into Q&A.
Questions and Answers:
Judah C. Frommer - Crédit Suisse AG - Research Division - Senior AnalystIf the audience does have questions that they'd like to ask, they can certainly send them over to me via e-mail, [email protected]. So first, maybe we could start out with a little bit of background. And in this same place about 12 months ago, you guys were a little bit away from in EUA. Since then, obviously, millions of people have received the Spikevax COVID -- the Spikevax COVID vaccine. The general pipeline has advanced, and there have been announcements regarding several research initiatives and manufacturing partnerships.
Trustpilot
